Accessibility Menu
Fresenius SE & Co logo

Fresenius SE & Co(OTC) FSNUF

Current Price$53.13
Market Cap$30.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-68%
5 Year+17%
1 Year+11%
1 Month+0%
Fresenius SE & Co last closing stock price
MetricPriceDate
Last closeUSD 54.352026-07-13
Fresenius SE & Co stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 54.352026-06-30
1 month+0%USD 54.352026-06-10
3 month+2.3%USD 53.132026-03-26
Year to date-0.54%USD 54.652025-12-30
1 year+11.2%USD 48.882025-07-11
3 year+104.71%USD 26.552023-07-11
5 year+16.66%USD 46.592021-07-12
Since inception-67.57%USD 163.812006-08-18

Fresenius SE & Co Financials at a Glance

Market Cap

$30.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€23.07B

Net Income (TTM)

€1.47B

EPS (TTM)

$3.03

P/E Ratio

17.95

Dividend

$1.22

Beta (Volatility)

-0.00 (Low)

Price

$53.13

Volume

51

Open

$51.92

Previous Close

$53.13

Daily Range

$51.92 - $53.13

52-Week Range

$46.21 - $58.16

Estimated Earnings Date

Aug 5, 2026

FSNUF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fresenius SE & Co

Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. The company operates through four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed.

Products and Services
  • Fresenius Medical Care specializes in dialysis products and services
  • Fresenius Kabi offers intravenous pharmaceuticals and nutritional solutions
  • Fresenius Helios manages a network of hospitals and outpatient clinics
Growth Outlook
  • Fresenius Medical Care continues to expand its global dialysis services
  • Fresenius Kabi is increasing its portfolio of biosimilar drugs
  • Fresenius Helios is enhancing its healthcare facility network in Europe
Financial Highlights
  • Recent quarterly revenue of €5.84 billion reflects strong operational performance
  • Trailing twelve months (TTM) net income of €1.43 billion indicates solid profitability
  • Dividend yield of 2.47% demonstrates commitment to returning value to shareholders
Fresenius SE & Co. KGaA has established itself as a leader in the healthcare sector, with a diverse range of products and services that cater to various medical needs. The company's focus on innovation and expansion positions it well for future growth, particularly in its dialysis and pharmaceutical divisions. Recent financial performance highlights a robust revenue stream and profitability, making it an attractive option for potential investors interested in the healthcare industry. The commitment to shareholder returns through dividends further underscores the company's financial health and strategic direction.
AI Generated • Jul 5, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

177,783

CEO

Michael Sen, MBA

Website

www.fresenius.de

Headquarters

Bad Homburg vor der Höhe, HE 61352, DE

FSNUF Financials

Key Financial Metrics (TTM)

Gross Margin

25.25%

Operating Margin

9.45%

Net Income Margin

6.38%

Return on Equity

7.76%

Return on Capital

7.02%

Return on Assets

3.47%

Earnings Yield

5.57%

Dividend Yield

2.24%

Payout Ratio

46.33%

Stock Overview

Market Cap

$30.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

563.24M

Volume

51

Avg. Volume

1.18K

Financials (TTM)

Gross Profit

€5.82B

Operating Income

€2.19B

EBITDA

€3.35B

Operating Cash Flow

€2.93B

Capital Expenditure

-€1.48B

Free Cash Flow

€1.45B

Cash & ST Invst.

€2.07B

Total Debt

€11.95B

Fresenius SE & Co Performance Analysis

Fresenius SE & Co annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 22,416,231,199-48.8%
20232023-12-31EUR 22,775,862,4081.6%
20242024-12-31EUR 23,747,438,8644.3%
20252025-12-31EUR 25,813,963,4648.7%
Fresenius SE & Co sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1.2%
Q32025-09-30-1.5%
Q42025-12-3112.0%
Q12026-03-31-5.1%
Fresenius SE & Co annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.57-33.3%
20232023-12-31EUR -1.14N/A
20242024-12-31EUR 0.90N/A
20252025-12-31EUR 2.53180.0%
Fresenius SE & Co sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3041.5%
Q32025-09-305.2%
Q42025-12-314.9%
Q12026-03-3120.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€5.84B

+3.4%

Gross Profit

€1.54B

+9.2%

Gross Margin

26.38%

N/A

Market Cap

$30.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$174.72K

N/A

Employees

175,202

N/A

Net Income

€436.65M

+90.7%

EBITDA

€905.42M

-4.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€2.07B

-18.3%

Total Debt

€11.95B

-12.3%

Accounts Receivable

€5.70B

+10.5%

Inventory

€2.74B

+4.0%

Long Term Debt

€9.57B

-16.0%

Short Term Debt

€2.37B

+5.9%

Return on Assets

3.47%

N/A

Return on Invested Capital

6.63%

N/A

Free Cash Flow

€159.60M

+229.8%

Operating Cash Flow

€406.54M

+626.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RSMDFResMed Inc.
$16.72+0.00%
SDZNYSandoz Group AG
$77.92-1.47%
OTSKYOtsuka Holdings Co., Ltd.
$34.02+2.93%
TRUMYTerumo Corporation
$13.25+1.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%

Questions About FSNUF

What is the current price of Fresenius SE & Co?

Fresenius SE & Co is trading at $53.13 per share.

What is the 52-week range for Fresenius SE & Co?

Over the past 52 weeks, Fresenius SE & Co has traded between $46.21 and $58.16.

How much debt does Fresenius SE & Co have?

As of the most recent reporting period, Fresenius SE & Co reported total debt of €13.72B.

How much cash does Fresenius SE & Co have on hand?

Fresenius SE & Co reported €2.37B in cash and cash equivalents in its most recent financial results.

What is Fresenius SE & Co’s dividend yield?

Fresenius SE & Co currently has a dividend yield of 2.24%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services